Amplia Therapeutics
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAAmplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer.
FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
Contact Details
Level 29, 55 Collins Street, MELBOURNE VIC 3000
02 8003 3650
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 30/09/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 126th | Amplia Therapeutics | 103% | 18% |
1743 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Amplia Therapeutics | $4.5m |
1333 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Jane Bell, Non-Executive Director | 19 Apr 2021 |
| NEW ROLE: Robert Peach, Non-Executive Director | 19 Apr 2021 |
| NEW ROLE: Jeff Carter, CEO and Managing Director | 24 Nov 2020 |
| NEW ROLE: Janette Dixon, | 24 Nov 2020 |
| NEW ROLE: Gill Webster, | 24 Nov 2020 |
| NEW ROLE: Andrew Cooke, Company Secretary | 03 Nov 2020 |
| NEW ROLE: John Lambert, Chief Executive, Managing Director since 2020 | 03 Nov 2020 |
| NEW ROLE: Colin Boyan, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Warwick Tong, Non-Executive Chair | 03 Nov 2020 |
